SR One Capital Management, LP — 13F Holdings & Portfolio
CIK 1910264 · latest 13F-HR filed 2026-08-12
SR One Capital Management, LP manages $1.04B in 13F-reported U.S. long-equity assets across 15 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are MANE (28.42%), ZBIO (12.31%), CRSP (10.70%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 2; 7 existing positions rose in reported value and 3 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-12
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- Veradermics, Inc.$143.6M +94.7%
- Zenas BioPharma, Inc$29.4M +29.8%
- Design Therapeutics, Inc.$25.0M +36.0%
- CRISPR Therapeutics AG$14.2M +14.7%
- Alumis Inc.$12.0M +27.7%
Top Trims
- ORIC Pharmaceuticals, Inc.-$8.5M -14.5%
- Oculis Holding AG-$8.2M -47.8%
- enGene Holdings Inc.-$3.8M -74.6%
New Positions
- Avalyn Pharma, Inc$108.9M
- Odyssey Therapeutics, Inc.$71.0M
- Mobia Medical, Inc$26.6M
SR One Capital Management, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Veradermics, Inc. | MANE | 922967104 | $295.3M | 28.42% | 2,401,868 | SH |
| 2 | Zenas BioPharma, Inc | ZBIO | 98937L105 | $127.9M | 12.31% | 5,037,854 | SH |
| 3 | CRISPR Therapeutics AG | CRSP | H17182108 | $111.2M | 10.70% | 2,038,763 | SH |
| 4 | Avalyn Pharma, Inc | AVLN | 05348Y105 | $108.9M | 10.48% | 3,308,649 | SH |
| 5 | Design Therapeutics, Inc. | DSGN | 25056L103 | $94.4M | 9.09% | 6,526,476 | SH |
| 6 | Odyssey Therapeutics, Inc. | ODTX | 67613T104 | $71.0M | 6.83% | 3,794,883 | SH |
| 7 | Alumis Inc. | ALMS | 022307102 | $55.2M | 5.31% | 1,959,896 | SH |
| 8 | ORIC Pharmaceuticals, Inc. | ORIC | 68622P109 | $50.0M | 4.81% | 4,615,384 | SH |
| 9 | Mineralys Therapeutics Inc. | MLYS | 603170101 | $42.2M | 4.06% | 1,563,966 | SH |
| 10 | ARS Pharmaceuticals, Inc. | SPRY | 82835W108 | $32.1M | 3.09% | 4,012,903 | SH |
| 11 | Mobia Medical, Inc | MOBI | 60705V103 | $26.6M | 2.56% | 1,986,072 | SH |
| 12 | Nkarta, Inc. | NKTX | 65487U108 | $9.4M | 0.91% | 3,333,333 | SH |
| 13 | Oculis Holding AG | OCS | H5870P102 | $8.9M | 0.86% | 641,022 | SH |
| 14 | Ultragenyx Pharmaceutical Inc. | RARE | 90400D108 | $4.6M | 0.44% | 137,753 | SH |
| 15 | enGene Holdings Inc. | ENGNW | 29286M105 | $1.3M | 0.12% | 747,750 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-12 | $1.04B | 15 | 0001193125-26-347065 |
| 2026-03-31 | 2026-05-14 | $915.4M | 14 | 0001193125-26-224136 |
| 2025-12-31 | 2026-02-12 | $706.4M | 13 | 0001193125-26-048808 |
| 2025-09-30 | 2025-11-12 | $691.4M | 12 | 0001193125-25-277769 |
SUITE 200
REDWOOD CITY, CA 94063